Indication
Major depressive disorder
Major depressive disorder is a common, disabling psychiatric mood disorder primarily affecting the central nervous system across pediatric, adult, and geriatric populations. Read more about Major depressive disorder
666 drugs 179 manufacturers
Drugs that treat it
Common Major depressive disorder therapies.
BUPROPION HCL SR (bupropion HCl)
MIRTAZAPINE
MIRTAZAPINE
ESCITALOPRAM OXALATE
ESCITALOPRAM OXALATE
KHEDEZLA (desvenlafaxine)
SARAFEM (fluoxetine HCl)
FETZIMA (levomilnacipran HCl)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMajor depressive disorder is a common, disabling psychiatric mood disorder primarily affecting the central nervous system across pediatric, adult, and geriatric populations.
It is clinically defined by persistent depressed mood or profound anhedonia lasting at least two consecutive weeks, accompanied by significant distress or impairment in social, occupational, and physical functioning.
Diagnostic features include alterations in sleep and appetite, psychomotor agitation or retardation, fatigue, impaired concentration, inappropriate feelings of worthlessness or guilt, and recurrent suicidal ideation.
Pathophysiologically, the condition involves complex multifactorial disruptions across monoaminergic neurotransmission, neuroplasticity, inflammatory signaling, and hypothalamic-pituitary-adrenal axis regulation.
- nih.gov
Major depressive disorder is a common, disabling psychiatric mood disorder primarily affecting the central nervous system across pediatric, adult, and geriatric populations Pathophysiologically, the condition involves complex multifactorial disruptions across monoaminergic neurotransmission, neuroplasticity, inflammatory signaling, and hypothalamic-pituitary-adrenal axis regulation
- nih.gov
Major depressive disorder is a common, disabling psychiatric mood disorder primarily affecting the central nervous system across pediatric, adult, and geriatric populations Pathophysiologically, the condition involves complex multifactorial disruptions across monoaminergic neurotransmission, neuroplasticity, inflammatory signaling, and hypothalamic-pituitary-adrenal axis regulation
- nih.gov
It is clinically defined by persistent depressed mood or profound anhedonia lasting at least two consecutive weeks, accompanied by significant distress or impairment in social, occupational, and physical functioning Pathophysiologically, the condition involves complex multifactorial disruptions across monoaminergic neurotransmission, neuroplasticity, inflammatory signaling, and hypothalamic-pituitary-adrenal axis regulation
- nih.gov
It is clinically defined by persistent depressed mood or profound anhedonia lasting at least two consecutive weeks, accompanied by significant distress or impairment in social, occupational, and physical functioning Diagnostic features include alterations in sleep and appetite, psychomotor agitation or retardation, fatigue, impaired concentration, inappropriate feelings of worthlessness or guilt, and recurrent suicidal ideation
- nih.gov
Diagnostic features include alterations in sleep and appetite, psychomotor agitation or retardation, fatigue, impaired concentration, inappropriate feelings of worthlessness or guilt, and recurrent suicidal ideation
Personalize your experience
Follow Major depressive disorder and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.